Autograph,Lester,rakousko24.cz,Collectibles Fine Art , Entertainment , Contracts,Signed,/heartbeat190078.html,Resume,Rawlins,-,$251 Lester Rawlins - Signed Autograph OFFicial shop Resume $251 Lester Rawlins - Autograph Resume Signed Collectibles Fine Art Entertainment Contracts Lester Rawlins - Signed Autograph OFFicial shop Resume $251 Lester Rawlins - Autograph Resume Signed Collectibles Fine Art Entertainment Contracts Autograph,Lester,rakousko24.cz,Collectibles Fine Art , Entertainment , Contracts,Signed,/heartbeat190078.html,Resume,Rawlins,-,$251

Lester Rawlins - Signed Autograph San Francisco Mall OFFicial shop Resume

Lester Rawlins - Autograph Resume Signed

$251

Lester Rawlins - Autograph Resume Signed

|||

Product description

LESTER RAWLINS The actor's handwritten resume from the archive of Theatre World and Screen World, a comprehensive record of American stage and film since 1945 Autograph Resume signed, 1 page, 8½x11. New York City, no date. Printed biographical form on which signer has supplied details: date and place of birth, education and professional training, and stage and screen experience. Theatre World, founded in 1945 by Daniel Blum, is America's oldest annual record of Broadway, Off-Broadway and regional theatre, referenced by industry professionals, historians, students and theatre fans worldwide. Until 1998, when a separate nonprofit corporation was established, Theatre World's editorial staff bestowed the prestigious Theatre World Awards for outstanding Broadway and Off-Broadway debuts. Screen World (from 1950) and Dance World (from 1966), administered from the same office, furnished comprehensive information on those entertainment genres. John A. Willis (1916-2010), active in Theatre World from the beginning, became its chief editor in 1965, holding that position until 2008. Willis is regarded as one of the foremost theatre and film historians of the 20th century. While producing (and presenting) the annual Theatre World Awards, Willis also served on the nominating committee for the Tony Awards. Theatre World, which received its own Tony for Excellence in Theatre in 2001, continues under chief editor Ben Hodges. Normal mailing folds. Lightly creased. Minimally toned at edges. Otherwise, fine condition. - Please contact us if you have any questions or require additional information. HFSID 304390

Lester Rawlins - Autograph Resume Signed

Since Jan 2010, Selleckchem products have been cited in 415 studies from top scientific journals.

Thirteen Nobel Prize winners have published 44 articles with Selleck products.

THE NOBEL PRIZE

Michael Houghton

Won the Nobel Prize in Physiology or Medicine in 2020

James P. Allison

Won the Nobel Prize in Physiology or Medicine in 2018

Michael Rosbash

Won the Nobel Prize in Physiology or Medicine in 2017

Eric Richard Kandel

Won the Nobel Prize in Physiology or Medicine in 2000

Brian K. Kobilka

Won the Nobel Prize in Chemistry in 2012

Robert Lefkowitz

Won the Nobel Prize in Chemistry in 2012

Aaron Ciechanover

Won the Nobel Prize in Chemistry in 2004

New Products

Catalog No. Product Name Target Pathway Information
S8944 G150 Others Others G150 is a potent and highly selective human cyclic GMP-AMP synthase (h-cGAS) inhibitor with IC50 of 10.2 nM.
S8913 TH5487 Others Others TH5487 is a selective active-site inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1) with IC50 of 342 nM.
S8938 KGA-2727 SGLT GPCR & G Protein KGA-2727 is a potent, selective, high-affinity inhibitor of sodium glucose cotransporter 1 (SGLT1) with Ki of 97.4 nM and 43.5 nM for human SGLT1 and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 exhibits antidiabetic efficacy in rodent models.
S8939 Mizagliflozin SGLT GPCR & G Protein Mizagliflozin is a novel, potent, selective sodium glucose co-transporter 1 (SGLT1) inhibitor with Ki of 27 nM for human SGLT1. The selectivity ratio (Ki value for human SGLT2/Ki value for human SGLT1) of mizagliflozin is 303. Mizagliflozin shows the potential use for the amelioration of chronic constipation.
S7013 Guadecitabine (SGI-110) Others Others Guadecitabine (SGI-110) is a next-generation hypomethylating agent whose active metabolite decitabine has a longer in-vivo exposure time than intravenous decitabine.
S8812 CM272 DNA Methyltransferase Epigenetics CM-272 is a novel first-in-class dual reversible inhibitor of G9a (GLP) and DNMTs with IC50 of 8 nM, 382 nM, 85 nM, 1200 nM, 2 nM for G9a, DNMT1, DNMT3A, DNMT3B, GLP, respectively. CM-272 prolongs survival in in vivo models of haematological malignancies by at least in part inducing immunogenic cell death.
S9729 Visomitin (SKQ1) Others Others INT-777 (S-EMCA) is a novel potent and selective TGR5 agonist with EC50 values of 0.18 μM, 3.9 μM and 1.45 μM for WT TGR5, TGR5(N76A) and TGR5(Y89F) respectively.
S8500 BAY1125976 Akt PI3K/Akt/mTOR BAY 1125976 is a selective allosteric AKT1/2 inhibitor,exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. BAY1125976 inhibits the activity of AKT1 (IC50 = 5.2 nM at 10 µM ATP and 44 nM at 2 mM ATP) and AKT2 (IC50 = 18 nM at 10 µM ATP and 36 nM at 2 mM ATP) very potently.Whereas BAY1125976 is almost inactive on AKT3 (IC50 = 427 nM at 10 µM ATP).
More
Tags: kinase inhibitors, tyrosine kinase inhibitors, enzyme inhibitors, protein inhibitors, proteins kinase inhibitors, small molecules, phosphatase inhibitors